Person:
İLHAN, MAHMUT MUZAFFER

Loading...
Profile Picture
Status
Organizational Units
Organizational Unit
Job Title
First Name
MAHMUT MUZAFFER
Last Name
İLHAN
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 34
  • PublicationMetadata only
    Respiation in Acromegalic patients
    (2012-04-15) AKKOYUNLU, MUHAMMED EMİN; KARAKÖSE, FATMANUR; İLHAN, MAHMUT MUZAFFER; KART, LEVENT; KUTBAY ÖZÇELİK, HATİCE; BAYRAM, MEHMET; SEZER, MURAT; TAŞAN, ERTUĞRUL; AKKOYUNLU, MUHAMMED EMİN; OKYALTIRIK, FATMANUR; İLHAN, MAHMUT MUZAFFER; BAYRAM, MEHMET; TAŞAN, ERTUĞRUL
  • PublicationMetadata only
    Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
    (2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    Objectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.
  • PublicationMetadata only
    A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus
    (2016-03-01) Ilhan, MAHMUT MUZAFFER; Tiryakioglu, N. O.; KARAMAN, O.; Coskunpinar, E.; YILDIZ, R. S.; TURGUT, SEDA; Tiryakioglu, D.; TOPRAK, HÜSEYİN; TASAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TOPRAK, HÜSEYİN; TAŞAN, ERTUĞRUL
    Purpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI.
  • PublicationMetadata only
    Tip 1 Diabetes Mellituslu Obez Olguda Bariyatrik Cerrahinin Etkisi
    (2017-05-03) YASİN, AYŞE İREM; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; MUTLU, EMİNE; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; MUTLU, EMİNE; TAŞAN, ERTUĞRUL
  • PublicationMetadata only
    Hipoglisemi sendromunun fotopletismografi ve elektriksel deri iletkenliği sinyalleri üzerindeki etkisi
    (2014-09-25) OKKESİM, ŞÜKRÜ; ÇELİK, GAMZE; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN
  • PublicationMetadata only
    Orucun beyin üzerindeki mikroyapısal etkisinin difüzyon tensör görüntüleme ile değerlendirilmesi
    (2014-11-16) BAKAN, AYŞE AHSEN; YILDIZ, ŞEYMA; ALKAN, ALPAY; YETİŞ, HÜSEYİN; KURTCAN, SERPİL; İLHAN, MAHMUT MUZAFFER; YILDIZ, ŞEYMA; ALKAN, ALPAY; KURTCAN, SERPİL; İLHAN, MAHMUT MUZAFFER
  • PublicationMetadata only
    Bariatrik Cerrahi Planlanan Morbid Obez Bireylerde Beden Algisi, Benlik Saygisi Ve Cinselhayat Kalitesinin İncelenmesi
    (2016-05-15) EKİNCİ, ESRA; BIKMAZ, PERVİN SEVDA; EKİNCİ, İSKENDER; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
  • PublicationMetadata only
    Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey
    (2015-01-01T00:00:00Z) Tasan, ERTUĞRUL; HANIMOGLU, Hakan; Turgut, SEDA; Ilhan, MAHMUT MUZAFFER; EVRAN, Sevket; KAYNAR, Mehmet Yasar; TAŞAN, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER
    Giant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.
  • PublicationMetadata only
    Hipofizer ve adrenal cushing sendromu birlikteliği
    (2014-05-21) KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; YASİN ÇETİN, AYŞE İREM; HAMDARD, JAMSHID; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER
  • PublicationMetadata only
    Atipik Subakut Tiroidit Olgusu
    (2017-05-03) KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; YASİN, AYŞE İREM; DAE, SHUTE AILIA; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; İLHAN, MAHMUT MUZAFFER; DAE, SHUTE AıLıA; TAŞAN, ERTUĞRUL